Madrigal Pharmaceuticals (MDGL) Share-based Compensation (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Share-based Compensation for 17 consecutive years, with $35.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Share-based Compensation rose 40.59% year-over-year to $35.4 million; the TTM figure through Jun 2026 stood at $121.4 million (up 155.69% YoY), while the FY2025 annual figure was $98.1 million, up 7448.46% from the prior year.
• Share-based Compensation advanced to $35.4 million in Q2 2026 per MDGL's latest filing, from $34.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $35.4 million in Q2 2026 and bottomed at -$33.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $13.7 million across 5 years, with a median of $12.0 million in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 511.82% — and 2025, when it jumped 12794.0%.
• Madrigal Pharmaceuticals' Share-based Compensation stood at $8.1 million in 2022, then sank by 511.82% to -$33.3 million in 2023, then soared by 100.6% to $200000.0 in 2024, then surged by 12794.0% to $25.8 million in 2025, then surged by 37.16% to $35.4 million in 2026.
• Business Quant data shows MDGL's Share-based Compensation at $35.4 million in Q2 2026, $34.0 million in Q1 2026, and $25.8 million in Q4 2025.